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tAbstract 
The application and utility of melanoma sentinel lymph node biopsy (SLNB) has evolved 
significantly since its inception over 2 decades ago.  The current focus has shifted from a staging 
modality to potentially a therapeutic intervention.  Recent research to include large multi-
institutional randomized trials have attempted to answer the question:  is a completion lymph 
node dissection (CLND) required following a positive SLNB?  This review provides an 
evidence-based, contemporary review of the utility of CLND for SLNB positive head and neck 
cutaneous melanoma patients. 
Level of Evidence: N/A 
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Introduction 
 The incidence of melanoma continues to climb at staggering rates with 87,110 new 
invasive cases projected in the United States for 2017 and an additional 9,730 melanoma deaths 
this same year.
1
  Regional metastasis remains the most important prognostic factor for melanoma 
recurrence and survival which underscores the importance of accurate staging.
2
  Up to 20% of 
melanoma patients presenting with localized stage I and II disease will actually  harbor occult 
regional metastasis despite a clinically and radiographically N-0 neck.  For this reason Dr. 
Donald Morton introduced the sentinel lymph node biopsy (SLNB) technique in 1992 as a means 
to identify these patients with aggressive melanoma who may benefit from additional therapy to 
include completion lymphadenopathy (CLND) and adjuvant therapy.
3
   
Since its inception, SLNB has replaced elective neck (END) as standard of care for 
staging of localized melanoma because 4 prospective randomized trials failed to demonstrate a 
survival benefit with END.
4-7
  Ultimately head & neck (HN) SLNB emerged as a reliable staging 
modality, more so than END and alternative imaging techniques.   In the ensuring 2 decades, 
SLNB was formally incorporated into American Joint Committee on Cancer staging system
2
 as 
well as evidenced-based national
8-10
 and international guidelines
11,12
.  Currently the World 
Health Organization recommends use of the technique for accurate staging of patients enrolled 
into clinical trials.  Ultimately dedicated HN studies definitively demonstrated that SLNB is safe 
and reliable in the HN region
13-15
, carrying the same false rate of emission of 4.2% as trunk and 
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textremity SLNB16.   The pathologic status of the sentinel node is recognized as the most 
important prognostic feature for disease recurrence and overall survival.
16 
 Current evidence based guidelines to include the National Comprehensive Cancer 
Network recommend CLND for all patients with a positive SLNB
8
.  The rationale for CLND is 
that uncontrolled regional disease will ultimately lead to systemic metastasis with decreased 
survival.   However this practice is variable and recent studies challenge the need and associated 
benefit afforded by CLND because patients with negative SLNB are at risk for subsequent 
distant disease.
17-19
  This state of the art review provides an evidence-based, contemporary 
review of the utility of CLND for sentinel node positive HN cutaneous melanoma patients.   
Current practice of Completion Lymph Node Dissection (CLND) 
 Current National Comprehensive Cancer Network (NCCN) guidelines advocate the use 
of SLNB for patients with localized Stage I and II melanoma, as well as patients with resectable 
satellite and in transit disease.
8
  Specifically, patients with Stage IB (0.76-1.0 mm thickness with 
≥ 1 mitotic feature/mm
2
 or Stage II > 1.0 mm thickness) should also be offered SLNB.  Stage IA 
patients (0.76-1.0mm thickness in the absence of ulceration and/or increased mitotic rate) should 
have the opportunity to discuss and consider SLNB staging.   
Per NCCN guidelines, patients with SLNB-positive stage III nodal disease should be 
offered a CLND.
8
  Panel members acknowledge the increased cost and morbidity associated with 
immediate CLND.  At the same time they highlight benefits of CLND to include: the increased 
known probability of additional positive non-SLNs, improved regional control, lower morbidity 
when compares to TLND, and potential to improve long-term disease specific survival (DSS) in 
these aggressive tumors.
8 
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t While CLND following a positive SLNB is standard of care, review of the National 
Cancer Data Base (2004-2005) revealed only 50% of patients with a positive SLNB undergoing  
CLND.
20
 Patients were more likely to undergo CLND if care was rendered in an NCCN or NCI-
designated center; patients were more likely to be observed if they were > 75 years of age or had 
an extremity melanoma. 
Mosquiera et al utilized the Surveillance Epidemiology and End Results (SEER) registry 
to conduct a population based analysis of intermediate thickness (1-4mm depth of invasion) 
melanoma patients undergoing CLND.
21
  13% of the 2172 study patients were primary HN.  91 
patients with HN melanoma underwent SLNB + observation; 190 HN patients underwent SLNB 
+ CLND for regional disease.  Overall, 68% of HN patients received CLND which mirrored that 
of trunk melanoma (70%) but was significantly higher than extremity melanoma (65%; p=0.05).  
CLND correlated with male gender (OR: 1.27), geographic location (Michigan OR=2.31; Iowa 
OR=1.69) and younger age.  While male gender, primary site, ulceration, depth of invasion, 
Clark level of invasion and number of positive lymph nodes were associated with survival 
(p<0.05), CLND did not reach statistical significance (p=0.83).  The study demonstrated < 2% 5-
year DSS advantage following CLND which was not significantly different from observation 
alone (70.4 vs 72.3; p=0.83).    
Prognostic Heterogeneity of SLN-positive Patients 
 Patients with a positive SLNB represent a heterogeneous cohort with survival rates 
ranging from a promising 90% to a dismal 30%.
22
  SLN tumor burden is a recognized prognostic 
factor with high tumor volume patients portending a worse prognosis.
22-24
  Tumor burden is 
defined as the maximum diameter of the largest metastatic deposit without lymphocytic 
interruption.  Consensus has not been reached as to the specific cut-point between high versus 
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tlow tumor burden.  Several studies demonstrate a similar disease free survival (DFS) and 
melanoma specific survival (MSS) rate between SLN-negative and SLN-positive patients with 
tumor burden measuring < 0.1mm.
25-27
 Scheri et al demonstrated a significant change in MSS 
when the minimal tumor burden cut point was increased from <0.1mm (90% MSS) to 0.2mm 
(80% MSS).
28
  It is important to note that SLN pathology sectioning protocols significantly 
impact patients classified.  Patients initially deemed low SLN tumor burden (<0.1mm) will 
actually be harboring high tumor burden identified only after additional SLN cuts are made for 
pathologic evaluation.
29  
A current standardized pathology protocol for assessing SLN tumor 
burden does not exist.
30 
 Tumor penetrative depth (TPD) of the micrometastatic disease within the SLN also 
impacts prognosis.  The Dewar Criteria classifies patients based on subcapsular anatomic site.
31
  
Subcapsular metastasis is defined as melanoma cells confined to the subcapsular sinus or the 
paratrabecular region without associated irregularity.
31
   This location is found in approximately 
20-30% of patients and portends a better prognosis compared to metastatic melanoma beyond the 
subcapsular region.
29,31
  Alternatively, the S-classification divides TPD into 3 categories: S1 
(≤0.3mm), S2 (>0.3 to ≤ 1.0mm) and S3 (>1.0mm).
24
  Approximately 30% of SLN positive 
patients fall into the S1 category and have an improved survival over  S2 and S3 metastatic 
deposits.   The Rotterdam criteria is a similar classification with even integer TPD cut-points 
(<0.1mm, 0.1-1.0mm, >1.0mm).
32
  Approximately 10-15% of SLN positive patients harbor TPD 
<0.1mm and portend a better overall prognosis compared to deeper TPD.   
 Van der Ploeg et al combined the prognostic information from both tumor burden 
utilizing the Dewar criteria and TPD utilizing the Rotterdam criteria.
28  
Patients harboring < 
0.1mm tumor burden confined to the subcapsular region demonstrated an excellent overall 
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tmelanoma specific survival (MSS) with 95% 5-year and 10-year rates.  Unfortunately only 6% 
of SLN positive patients fall into this specific category. 
Therapeutic Value of CLND: Non-Randomized Trials 
 Numerous single institution and non-randomized trials investigated the survival benefit of 
CLND following a positive SLNB.  Bamboat et al. conducted a non-randomized study of their 
Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
33
  495 of their 4310 melanoma 
(11%) had a positive SLNB.  167 (34%) underwent observation while the remaining 328 (66%) 
underwent immediate CLND.  There was no difference between the two treatment arms with 
respect to tumor depth of invasion, Clark’s level of invasion, or ulceration.  The observation arm 
was significantly older (66 yrs vs 56 yrs; p<0.001) and was more likely to have a lower extremity 
melanoma.  Patients had a minimum of 23 months follow-up in the observation arm and 80 
months in the CLND arm.  There was no difference in local or in transit metastasis between the 
2 groups.  Patients in the observation arm were more likely to have a regional recurrence (15% 
versus 6%; p=0.002) while patients in the CLND arm were more likely to develop systemic 
recurrence (27% vs 8%; p<0.001).  16% of the SLN-positive patients who went on to CLND had 
additional positive non-SLNs.  Recurrence free survival (RSS) rates were higher in the CLND 
arm (34.5 vs 20.9 months; p=0.02) but MSS did not differ (p=0.09).   
 
 Wong et al. conducted an multi-institutional study among 16 melanoma centers to 
determine the impact of observation following a positive SLNB compared to historic controls.
34
  
The median age for the study cohort was 59 years.  The median depth of invasion was 2.6 mm.  
77% of all tumors were classified as Clark level 4/5 and 33% of the tumors were ulcerated.  Only 
12% of study patients had a primary melanoma involving the HN region.  134 patients were 
observed for a median period of 20 months which was shorter than the 36 month follow-up for 
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tthe 164 CLND.  Overall, 20 patients (15%) in the observation arm went on to develop nodal 
recurrence at a median time of 11 months.  The nodal RFS did not differ between the observation 
and CLND cohorts (p=0.07), and the DSS did not differ between the groups (p=0.65). 
 Kingham et al. conducted a prospective database study (1992-2008).
35
  Of the 2269 
patients undergoing SLNB, 313 had at least one positive node.  271 (87%) of patients received 
CLND, with the remaining 42 (13%) were observed with serial ultrasound for the first 2 years.  
Only 28 of the 313 patients (9%) were HN primaries. Patients in the observation cohort were 
older (70 yrs vs 56; p<0.01) and were more likely to have an extremity melanoma (40% vs 13%; 
P<0.01).  Patient refusal was the most common reason for observation (45%).  The observation 
cohort had a median follow-up of 32 months and the CLND cohort 43 months.  No difference 
was identified between the two groups with respect to location of first recurrence, RFS or DSS.  
Similarly, a retrospective EORTC trial included 1174 positive SLNB patients to compare CLND 
(n=1113) to observation (n=61).
36
  CLND did not impact DSS on univariate and multivariate 
analysis.    
Therapeutic Value of CLND: Randomized Trials 
 DeCOG-SLT is a multicenter, phase III trial randomizing SLN-positive patients to 
immediate CLND (n=241) versus observation with serial nodal ultrasound (n=242).
37
  The 
primary endpoint was distant metastasis-free survival.  At a median follow-up of 35 months, the 
authors reported no difference in 3-year distant metastatic rates between the CLND arm (75%) 
and the observation arm (77%).   Similarly, CLND did not impact RFS or overall survival (OS) 
beyond that of observation.  A slight improvement in regional control was noted with CLND 
(92% vs. 85%).  However multivariate analysis failed to identify CLND as an independent 
variable impacting distant metastatic-free survival, OS or RFS.  Overall, 34 (14%) of patients in 
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(n=3; 8.8%), seroma (n=3; 8.8%), infection (n=3; 8.8%), and wound healing complications 
(n=5;14.7%). 
There are several limitations of the trial.  331 patients (66%) had low tumor burden SLNs 
measuring ≤ 11mm.  As noted above this tumor burden is considered low risk.  The authors also 
acknowledge difficulties in accrual, disclosing that the study was under powered.   The original 
study was planned for 9 years, with an accrual period of 6 years to enroll 550 patients and detect 
a 10% difference in distant metastasis-free rate in the setting of a CLND.  After 8 years of 
accrual, only 473 patient met inclusion criteria.  Therefore, the principle investigators elected to 
close the trial early, acknowledging  that the study did not achieve the required number of events.   
DeCOG-SLT must be interpreted with caution for HN cutaneous melanoma patients.  
Most import ntly, this study excluded the HN subsite because the authors felt that the technique 
was “controversial” in the HN, citing a review article from 2011.
38
   Since that publication, the 
largest single institution, dedicated HN melanoma SLNB study prospectively followed 353 
patients for a mean of 48 months.
16
  4.24% of patients with a negative SLNB developed isolated 
regional recurrence.  The negative predictive value for a negative HN SLNB was reported as 
95.8% which mirrored that of trunk and extremity melanoma where the technique is considered 
standard of care.  
Results of the long awaited Second Multicenter Selective Lymphadenectomy Trial 
(MSLT-II) are published.
39  
This international, multi-institutional randomized prospective trial 
was designed to determine the value of CLND for patients with a positive SLN.  1934 were 
enrolled in the trial from 2004 – 2014.  824 patients underwent SLNB + CLND and 931 
underwent SLNB + observation.  At a median follow-up of 43 months, the 3-year MSS rate was 
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tsimilar between the CLND and observations arms (68% vs 86%; p=0.42).  The CLND arm did 
experience an improved DFS (68% vs 64%; p=0.05).  Regional control was also improved in the 
setting of CLND (92% vs 77%; p<0.001).  11.5% of patients undergoing CLND had additional 
positive non-SLNs identified on final pathology, and a positive non-SLN was an independent 
prognostic factor for recurrence (Hazard ration: 1.78; p=0.005).  Overall, the MSLT-II research 
team conclude that immediate CLND increased the rate of regional control and provided 
prognostic information but did not impact MSS among melanoma patients with a positive SLNB.  
The clinical implications of this trial for HN cutaneous melanoma warrants several 
considerations.  The representation of the HN subsite was small.  241 patients in the MSLT-II 
trial had HN cutaneous melanoma (13.7%); 113 underwent CLND and 128 observation.  
Subgroup analysis of the 3-year hazards ratio for MSS was not found to differ based on CLND 
(0.81; 0.44-1.48) versus observation following a positive SLNB (1.60; 0.96-2.66; p=0.07).  In 
addition, the authors stress the high rate of lymphedema following CLND, a complication rarely 
seen in the HN region (see below).   
The European Organization for Research and Treatment of Cancer (EORTC) Melanoma 
Group is currently conducting the Minimal Sentinel Node Tumor Burden (MINITUB) trial to 
investigate the ability for CLND to portent a therapeutic benefit and to identify patients who may 
potentially be spared the procedure without oncologic compromise.
40
  The estimated enrollment 
is 260 SLN positive patients randomized to observation versus CLND.  Inclusion criteria are 
metastasis limited to the SLN with either 1) subcapsular tumor burden ≤ 0.4mm and without 
parenchymal infiltration or 2) sub-micrometastatic disease ≤ 0.1mm regardless of node subsite.  
The primary outcome measure is distant metastasis-free interval.  Secondary outcomes include: 
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lymphedema and neurological damage.   Results from the trial are anticipated in 2023.  
CHALLENGES OF INTERPRETING THE CURRENT CLND DATA 
Paucity of Head and Neck Specific Data  
A paucity of data exists specific to HN cutaneous melanoma CLND.  As outlined above, 
large prospe tive multi-institutional studies often lump the HN subset of patients (who are 
known to carry a worse prognosis) with trunk and extremity melanoma or exclude the site 
altogether.  Given small representation of HN patients in CLND cutaneous melanoma studies, 
Lentsch et al. utilized the SEER database to investigate the ability for CLND to improve survival 
in the HN population.
41
  350 SLN positive patients were identified: 201 (60%) underwent SLNB 
+ CLND while 140 (40%) received SLNB alone + observation.  Overall, a 5-year DSS was not 
imparted following CLND.  However, a subset of younger patients (<60 years) with non-
ulcerated tumors measuring a depth of invasion ≤ 2mm benefited from immediate CLND 
(p=0.03).  Interestingly, it is this same patient demographics that benefited from END in the prior 
Intergroup Melanoma Surgical Trial (IMST) back in 2000.
42
  This finding leaves in question the 
ability to rely on prognostic features to forgo CLND in the younger patient population; the 
authors warn that younger patients traditionally deemed low risk for metastatic recurrence may 
actually miss their window for curative intervention if CLND is not performed.   
While the strength of this investigation is the specific focus on the HN subsite, the 
retrospective nature inherent to database reviews remains a bias.  In addition, the SEER database 
only represents 28% of the patient population.  Lastly, the authors acknowledge that information 
is unavailable with respect to surgical margin status, adjuvant therapy, and the differentiation 
between positive SLNs versus non-SLNs in the registry.     
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Lack of standardized pathology protocols for evaluation of non-SLNs 
 Non-sentinel lymph node (non-SLN) status is another recognized prognostic feature for 
the cutaneous HN melanoma patient population; however, the data is conflicting.
43
  Numerous 
studies attempted to identify SLN positive patients who are at risk for additional positive non-
SLNs (identified following CLND).  While primary tumor depth of invasion and SLN 
characteristics (see above) have emerged as prognostic markers in some investigations, the 
outcomes are not consistently replicated.
 44-46
    
 In theory, patients with metastatic regional disease limited to SLNs alone should receive 
the lowest benefit from a CLND.  The SEER database was utilized to test this hypothesis 
specifically among HN melanoma patients.
47
   The primary study objectives were 1) to identify 
prognostic features associated with a low risk for harboring non-SLNs and 2) analyzing the 5-
year DSS between patients stratified on risk for non-SLN positivity.  210 patients in the national 
database received SLNB + CLND while 140 patient received SLNB alone.  Minimal tumor 
thickness (depth of invasion) and non-ulceration were both associated with a low risk of 
harboring non-SLN in the CLND specimen (p<0.25).  Patient age, anatomic site, and sex were 
not prognostic.  Patients < 60 years of age who underwent CLND had a markedly improved DSS 
compared to SLNB alone (>90% vs <25%; P<0.0025) but a DSS survival advantage with CLND 
over observation was not found in the subgroup deemed at higher risk for non-SLN metastasis 
(P>0.25).  The authors conclude that selecting patients for CLND based on non-SLN risk of 
metastasis may be unreliable. 
MSLT-II found that patients with positive non-SLNs portend a worse prognosis but at the 
current time a reliable way to identify this high risk subgroup is lacking.
39
  A recognized 
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tchallenge in identifying prognostic models for non-SLN positivity is the lack of standardized 
protocols for thorough evaluation of CLND nodes.  Wrightson et al retrospectively reviewed 117 
non-SLNs harvested from 13 patients who underwent CLND following a positive SLN biopsy.
48
  
Initially all 117 nodes harvested during CLND were deemed negative for metastasis on 
traditional hematoxylin and eosin staining.  However, 18 (15%) of the nodes were reclassified as 
positive following examination with reverse transcription polymerase chain reaction.   This 
change led to a staggering 7 of the 13 patients (54%) being reclassified as having positive non-
SLNs. 
Completion Lymphadenectomy Complications 
 The overall complication rates associated with CLND are extremely variable, ranging 
from 20% to 60%.
8   
Proponents for observation over CLND cite the higher complications rates 
and associated morbidity as part of their rationale.  Complications associated with CLND 
include: wound infection/dehiscence, hematoma, seroma, neuropathy, lymphocele, and 
lymphedema.  Lymphedema can impact as many as 50% of patients and carries and association 
with obesity, age, and groin dissection.
8
   
Moody et al. conducted a systematic review of the literature to investigated the associated 
postoperative morbidity associated with a CLND following SLNB compared to a TLND 
following regional recurrence in patients observed following a positive SLNB.
49
  18 article met 
inclusion criteria.  A surgical complication rate of 39.3% was reported in the 1627 undergoing 
TLND which mirrored the 37.2% reported among 1929 patients receiving CLND.     
The applicability of the above cite complications within the HN patient population 
remains in question.  The most recent MSLT-II trial reported a statistically higher rate of 
lymphedema in the setting of CLND (24.1%) compared to 6.3% in the observation arm 
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t(p<0.001).39  However, lymphedema is a known complication of groin and extremity CLND, but 
does not carry the same challenges for the neck.     
CONCLUSIONS AND FUTURE ENDEAVORS 
 The data surrounding the need for CLND following a positive SLNB remains 
controversial.  HN cutaneous melanoma patients are a unique subset, carrying a worse prognosis 
compared to their trunk and extremity counterparts.  In addition, they do not traditionally suffer 
from the lymphedema often seen at other sites.  The importance of achieving regional control in 
the head and neck given proximity to critical structures (carotid artery, trachea, esophagus) bears 
thoughtful consideration. Regional failure in the head and neck can have significant implications 
on both quality and quantity of life.   
In order to truly determine the therapeutic utility of SLNB, large, prospective, 
randomized trials specific to the HN cutaneous melanoma population are required.  Prior to 
conducting such trials a standardized, evidence-based pathology protocol to evaluate of non-
SLNs in a meticulous fashion with incorporation of molecular analysis are also required.  In the 
interim, surgeons should have a candid conversation with their HN melanoma patients about 
CLND.  Ultimately the decision will be made based on surgeon experience and patient 
preference.    
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